As Covid rises again, killing about 1,500 Americans each week, medical researchers are trying to understand why so few people are taking Paxlovid, a medicine that is stunningly effective in preventing severe illness and death from the disease.
A new report published in Open Forum Infectious Diseases demonstrates that, despite the proven effectiveness of Paxlovid and molnupiravir against severe COVID-19 outcomes, uptake of these two antivirals remains low among Americans with COVID.
Vaccinated children are less likely than unvaccinated children to develop long COVID, the myriad of symptoms that can last for months to years following a SARS-CoV-2 infection, according to a forthcoming US study1.
Recent Comments